Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The deal is expected to close in the first quarter of 2018.
Pfizer acquired China/Asia rights for Cresemba, an antifungal drug developed by Swiss pharma Basilea, in a $226M deal.
Esaote S.p.A., an Italian medical imaging company, has been acquired by a group of China investors.
Medtronic confirmed that it bought Crospon but declined to disclose the value of the deal.
GlaxoSmithKline will scout for deal opportunities in cancer medicine, as well as immunology, as the drugmaker seeks to rebuild its presence in oncology, its new head of pharmaceuticals told Reuters.
The company indicates it plans to continue to manage and operate under the bankruptcy filing while it works with Cowen and Company to develop a plan forward.
Despite a purge of the leadership team at Alexion, a key investor believes the company needs to do more in order to address its damaged reputation and lift its stock price.
Sucampo has received takeover interest, although there are no hints about who has shown an interest.
With the raise, the company’s market valuation is currently $1.7B.
Gilead will pay an upfront payment of $175M, with additional milestone payments of up to $322M.